Prevention and Treatment of Spontaneous Mammary Carcinoma With Dendritic Tumor Fusion Cell Vaccine
Annual rept. 1 Jul 2000-30 Jun 2001
DANA-FARBER CANCER INST BOSTON MA
Pagination or Media Count:
We have developed a vaccine based on the fusions of DC with tumor cells The fusion cells express MHC class I and II, costimulatory molecules and tumor-derived peptides. Immunization with dendritictumor fusion cells FCMUC1 prevented MC38MUC1 tumor cell challenge and eradicated established MUC1-positive pulmonary metastasis in MUC1 transgenic mice MUC1.Tg In the present study MUC1 transgenic mice are crossed with strains that express polyoma middle T antigen MTag driven by the mouse mammary tumor virus MMTV-LTR promoter. The new breeder MMT mice develops spontaneous mammary carcinoma. We demonstrate that MMT or MT mice form mammary carcinoma with three stages 1 latent stage from new born to 3 weeks old. 2 premalignant stage from age of 4 weeks to 5 weeks. 3 stage of carcinoma formation from age of 6 weeks or older. Immunization with DCtumor fusion cells in the premalignant stage rendered the 78 mice tree of disease. These results match our hypothesis that immunization with fusion cells can generate an effective antitumor response to block the progression of premalignant lesion in MMT mice.
- Anatomy and Physiology
- Medicine and Medical Research